Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatocellular carcinoma and chemoembolization.

M Harris1, P Gibbs, J Cebon

  • 1Department of Medical Oncology, Austin & Repatriation Medical Centre, Melbourne, Victoria, Australia. marion.harris@ludwig.edu.au

Internal Medicine Journal
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Scientific reports·2018
Same author

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

British journal of cancer·2016
Same author

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.

The British journal of ophthalmology·2011
Same author

Fourier transform infrared imaging as a method for detection of HLA class I expression in melanoma without the use of antibody.

Tissue antigens·2007
Same author

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.

British journal of cancer·2006
Same journal

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Internal medicine journal·2026
Same journal

The paradox of peer review: protecting science or policing thought?

Internal medicine journal·2026
Same journal

Immune-related pancytopenia in pregnancy.

Internal medicine journal·2026
Same journal

Crossover effect: causal machine learning reveals opposing mortality responses to mean arterial pressure targets among phenotypically distinct hypertensive patients with septic shock.

Internal medicine journal·2026
Same journal

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral-treated human immunodeficiency virus infection.

Internal medicine journal·2026
Same journal

Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors.

Internal medicine journal·2026
See all related articles

Chemoembolization offers palliative treatment for hepatocellular carcinoma, with response rates and toxicity aligning with existing literature. New therapies and hepatitis B/C prevention are crucial for reducing mortality.

Area of Science:

  • Hepatobiliary Medicine
  • Interventional Oncology
  • Medical Imaging

Background:

  • Hepatocellular carcinoma (HCC) management often involves chemoembolization.
  • Limited data exists on chemoembolization efficacy in Australia.
  • This study reviews HCC patient outcomes in an Australian setting.

Purpose of the Study:

  • To retrospectively evaluate the efficacy and safety of chemoembolization for HCC.
  • To assess treatment response, toxicity, and survival in Australian patients.

Main Methods:

  • Retrospective review of 21 HCC patients undergoing 36 chemoembolizations.
  • Selective hepatic artery catheterization with a cisplatin, epirubicin, mitomycin C, Lipiodol, and gelfoam mixture.
  • Computed tomography (CT) scans for response assessment; outcomes included response rates, toxicity, progression-free survival (PFS), and overall survival (OS).

Related Experiment Videos

Main Results:

  • CT response rates: partial response (19%), minor response (17%), stable disease (42%), progressive disease (22%).
  • Median PFS was 3 months; median OS was 15 months.
  • Major toxicities included renal failure, encephalopathy, gastric ulceration, and hepatorenal failure.

Conclusions:

  • Chemoembolization plays a role in palliative HCC treatment.
  • Observed response rates and toxicity are consistent with published data.
  • Novel treatments and hepatitis B/C prevention are essential for reducing HCC mortality.